How Secondary Trades Pushed Neuralink to a $42 Billion Mark

Elon Musk's brain-chip startup Neuralink is changing hands at valuations as high as $42 billion in private secondary-market transactions, according to investor correspondence and data seen by Business Insider. That marks a nearly fivefold increase from the company's last official funding round in 2025, when it was valued at $9 billion.

The surge is being driven by soaring demand for Musk-related assets following the blockbuster IPO of SpaceX, now publicly traded around $1.6 trillion. Because Neuralink remains private, existing shares are sold by employees and early investors on secondary platforms, where prices reflect what new buyers are willing to pay rather than a company-led valuation. Caplight, a private-markets research provider, reports that recent trades have ranged from $29 billion to $42 billion, with some bidders even offering prices implying a near-$60 billion valuation.

The company builds implants designed to help people with paralysis control computers with their thoughts, with the long-term plan of restoring eyesight. The technology is still in early clinical stages; Neuralink announced earlier this year that its devices have been implanted in only 21 trial patients. The most recent publicly disclosed investment came in May, when Oman's sovereign wealth fund took a stake at an undisclosed price.

Why Investors Are Chasing Neuralink at Any Price

FOMO, the Musk Premium, and SpaceX Halo

The mania around Neuralink cannot be separated from Elon Musk's track record of delivering outsized returns to private investors. The recent history of combining his companies – where backers of X and xAI obtained SpaceX shares through acquisitions – has created a powerful incentive to buy into any Musk venture early, hoping for a similar liquidity path. One venture investor told Business Insider that multiple limited partners are asking to buy Neuralink shares 'at any price'.

Stark Disconnect Between Price and Progress

The $42 billion price tag sits uneasily next to the company's actual achievements. With only 21 patients enrolled in trials and no clear timeline for regulatory approval of a commercial product, the current secondary market bids are driven almost entirely by narrative and scarcity, rather than revenue or clinical milestones. While the technology is genuinely groundbreaking, it is still a pre-revenue, early-stage medical device company.

A Split Market and Illiquidity Risk

Not all investors are convinced. Caplight data shows a wide bid-ask spread, with some potential sellers already booking profits and others trying to buy, but a portion of the market is balking at the high prices. The lack of a continuous market and the fact that secondary trades estimate demand, not official value, means the $42 billion figure could evaporate quickly if Musk sentiment shifts or a new funding round sets a lower official valuation.

What This Means for Current and Prospective Neuralink Backers

  • Secondary market bids do not represent an official company valuation and can diverge sharply from a future funding round; treat the $42 billion figure as a demand signal, not a fundamental price anchor.
  • Early investors and employees selling at these levels may be booking gains after the 5x run-up, which removes natural holders and increases the risk of an overhang if sentiment sours.
  • The absence of a clear regulatory or commercial timeline means that any investment today is a bet on Musk's ability to orchestrate a liquidity event, not on Neuralink's standalone business momentum.
  • Oman's sovereign fund investment in May suggests that institutional capital is still willing to participate at undisclosed terms; keep an eye on any official funding round, as it will provide a concrete valuation reality check.
  • Musk's history of combining companies could provide alternative exit paths, but those are discretionary and should not be assumed; direct share positions remain highly illiquid until a public listing, acquisition, or secondary sale window.

Risk & Opportunity Assessment

Commercial RiskHighNeuralink is pre-revenue with only 21 trial patients; commercial viability and reimbursement pathways for brain implants are unproven, and the $42 billion secondary price reflects narrative rather than financial performance.
Competitive RiskMediumSynchron and other brain-computer interface startups are also progressing in clinical trials, though Neuralink benefits from Musk's capital and visibility.
Regulatory RiskHighBrain implants face rigorous FDA approval processes and potential safety concerns; any adverse event or delay could reset expectations abruptly.
Reputation RiskMediumThe wide gap between secondary valuations and tangible progress could damage Musk's credibility with investors if the company fails to deliver, especially after the hype built by the SpaceX halo.
Technology DisruptionHighIf Neuralink successfully commercializes a safe, effective implant, it could redefine treatment for paralysis and blindness, but the technology is still early and the outcome highly uncertain.
Commercial OpportunityHighMusk's track record of bundling companies and delivering returns has created a real opportunity for secondary buyers to gain indirect exposure to a future SpaceX-like liquidity event, provided they accept the illiquidity and binary risk.